Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Astellas Pharma Inc (ALPMY)

Astellas Pharma Inc (ALPMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 21,534,988
  • Shares Outstanding, K 1,809,663
  • Annual Sales, $ 10,620 M
  • Annual Income, $ 113,000 K
  • 60-Month Beta 0.38
  • Price/Sales 1.97
  • Price/Cash Flow 10.40
  • Price/Book 2.03
Trade ALPMY with:
  • Price/Earnings ttm 26.26
  • Earnings Per Share ttm 0.46
  • Most Recent Earnings $0.24 on 08/01/24
  • Next Earnings Date 11/06/24
  • Annual Dividend & Yield 0.32 (2.68%)
  • Most Recent Dividend 0.152 on 03/26/24
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.01
  • Growth Rate Est. (year over year) +9,990,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.0800 +10.65%
on 08/19/24
13.1400 -6.70%
on 08/29/24
+0.7400 (+6.42%)
since 08/16/24
3-Month
9.3500 +31.12%
on 06/20/24
13.1400 -6.70%
on 08/29/24
+2.7700 (+29.19%)
since 06/18/24
52-Week
9.1500 +33.99%
on 04/16/24
14.8800 -17.61%
on 09/19/23
-2.6500 (-17.77%)
since 09/18/23

Most Recent Stories

More News
Here Are the 3 George Soros Stocks Most Likely to Turn $200,000 Into $1 Million Over the Next 20 Years

The multibillionaire's portfolio features some moneymaking ideas.

ALPMY : 12.2600 (+3.03%)
GOOG : 160.81 (+0.33%)
GOOGL : 159.81 (+0.31%)
AMZN : 186.43 (-0.24%)
MSFT : 430.81 (-1.00%)
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?

Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects.

AMGN : 332.92 (+0.04%)
BMY : 49.74 (+0.51%)
LLY : 904.97 (-0.13%)
XLV : 155.36 (-0.17%)
HZNP : 116.30 (+0.04%)
JNJ : 166.15 (-0.55%)
MRK : 118.64 (+0.30%)
NVS : 115.97 (+0.23%)
NVO : 132.06 (+0.05%)
XPH : 44.61 (+0.63%)
ALPMY : 12.2600 (+3.03%)
Why Shares of Annexon Are Plummeting Thursday

Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock.

ISEE : 39.95 (+0.38%)
APLS : 35.63 (+0.28%)
ALPMY : 12.2600 (+3.03%)
ANNX : 6.93 (-0.86%)
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today

These three biotech stocks were on the volatile side today.

APLS : 35.63 (+0.28%)
TGTX : 25.25 (+0.68%)
VKTX : 64.45 (+2.40%)
ISEE : 39.95 (+0.38%)
ALPMY : 12.2600 (+3.03%)
Pfizer buys Seagen for $43B, boosts access to cancer drugs

Pfizer is spending about $43 billion to reach deeper into new cancer treatments that target tumor cells while sparing surrounding healthy tissue

ALPMY : 12.2600 (+3.03%)
$SPX : 5,618.26 (-0.29%)
$DOWI : 41,503.10 (-0.25%)
$IUXX : 19,344.49 (-0.45%)
PFE : 29.75 (-0.27%)
Got $1,000? Here's a Dirt-Cheap Big Pharma Stock to Buy

Pfizer should remain a pharma powerhouse long after the COVID-19 pandemic comes to an end.

PFE : 29.75 (-0.27%)
BNTX : 115.62 (-7.29%)
JNJ : 166.15 (-0.55%)
ALPMY : 12.2600 (+3.03%)
BMY : 49.74 (+0.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Astellas Pharma, Inc. is engaged in the research, development, manufacturing and marketing of pharmaceuticals drugs. Products offered by the Company include Prograf applicable for the prevention of rejection in organ transplants, Vesicare for treatment of overactive bladder, Protopic for the treatment...

See More

Key Turning Points

3rd Resistance Point 13.3365
2nd Resistance Point 12.9132
1st Resistance Point 12.4066
Last Price 12.2600
1st Support Level 11.4767
2nd Support Level 11.0534
3rd Support Level 10.5468

See More

52-Week High 14.8800
Fibonacci 61.8% 12.6911
Last Price 12.2600
Fibonacci 50% 12.0150
Fibonacci 38.2% 11.3389
52-Week Low 9.1500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar